APA

Berger M. S., Leopold L. H., Dowell J. A., Korth-Bradley J. M. & Sherman M. L. (20030421). Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. : Investigational new drugs.

Chicago

Berger Mark S, Leopold Lance H, Dowell James A, Korth-Bradley Joan M and Sherman Matthew L. 20030421. Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. : Investigational new drugs.

Harvard

Berger M. S., Leopold L. H., Dowell J. A., Korth-Bradley J. M. and Sherman M. L. (20030421). Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. : Investigational new drugs.

MLA

Berger Mark S, Leopold Lance H, Dowell James A, Korth-Bradley Joan M and Sherman Matthew L. Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. : Investigational new drugs. 20030421.